14.3 C
New York
Tuesday, March 21, 2023

bluebird bio Inc. (NASDAQ: BLUE) Could Achieve Gains In The Near Future

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for bluebird bio Inc. (BLUE) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.03, or 0.61%, to $4.98. The bluebird bio Inc. has recorded 105,468 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Stocks Info

bluebird bio Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $4.95 and fluctuated between $5.0750 as its day high and $4.9400 as its day low. The current market capitalization of bluebird bio Inc. is $525.34M. A total of 3.37 million shares were traded on the day, compared to an average of 3.43M shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, BLUE has seen 0 BUY and 3 SELL insider trades, representing the acquisition of 0 and the disposition of 8,025 shares. Over the last 12 months, there were 10 BUYs and 10 SELLs from insiders. Insiders purchased 115,561 shares during that period but sold 58,064.

In the most recent transaction, Leschly Nick sold 4,290 shares of BLUE for 7.80 per share on Jan 11. After the transaction, the Director now owns 280,149 company shares. In a previous transaction on Jan 11, Obenshain Andrew sold 3,178 shares at 7.80 per share. BLUE shares that President and CEO owns now total 242,690.

Among the insiders who sold shares, Colvin Richard A disposed of 557 shares on Jan 11 at a per-share price of $7.80. This resulted in the Chief Medical Officer holding 74,231 shares of BLUE after the transaction. In another insider transaction, Obenshain Andrew sold 1,263 shares at $6.41 per share on Nov 04. Company shares held by the President and CEO now total 245,868.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for BLUE in the last 3 months, the mean price target is $7.25 with high estimates of $10.00 and low estimates of $4.00. In terms of 52-week highs and lows, BLUE has a high of $8.58 and a low of $2.87.

As of this writing, BLUE has an earnings estimate of -$0.6 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of $1.26 per share and a lower estimate of -$1.18. The company reported an EPS of -$1.36 in the last quarter, which was -9.70% lower than expectations of -$1.24.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 10 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BLUE is Hold with a score of 2.80. A total of 0 analysts rated the stock as Buy while 1 rated it as Overweight while 7 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 2 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles